- Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adultsRobert W Frenck
Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
Vaccine 29:5666-74. 2011..The reduced 3 μg dose administered ID by needle and syringe, as well as the 6 μg ID for subjects aged 50-64 years of age generated poorer immune responses as compared to the 15 μg IM dose...
- The development of 13-valent pneumococcal conjugate vaccine and its possible use in adultsRobert W Frenck
Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, MLC 6014, Cincinnati, OH 45229, USA
Expert Opin Biol Ther 12:63-77. 2012..Pneumococcal conjugate vaccines (PCVs) have been developed for use in infants and children aged less than 5 years, and are being studied for use in adult populations...
- Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adultsRobert W Frenck
Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
Clin Vaccine Immunol 19:1296-303. 2012..Given the positive immunologic attributes of PCV13, concomitant administration with TIV should be dictated by clinical circumstances...
- Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccineRobert Frenck
Cincinnati Children s Hospital Medical Center, Department of Pediatrics, Cincinnati, OH 45229, USA
Pediatr Infect Dis J 30:1086-91. 2011..This open-label study evaluated the immunogenicity and safety of administering PCV13 to healthy children previously vaccinated with PCV7...